School of Medicine
Showing 241-260 of 729 Results
-
Benjamin Davies Horne
Adjunct Clinical Associate Professor, Medicine - Cardiovascular Medicine
BioDr. Benjamin Horne is an Adjunct Clinical Associate Professor who is based at the Intermountain Medical Center Heart Institute in Salt Lake City, UT, where he serves as the Director of Cardiovascular and Genetic Epidemiology. His doctoral training (PhD) in genetic epidemiology was completed at the University of Utah and he holds masters degrees in public health and in biostatistics. Dr. Horne is a fellow of the American Heart Association, a fellow of the American College of Cardiology, and a member of the American Society of Human Genetics. Dr. Horne’s research focuses on population health and precision medicine, including evaluating the genetic epidemiology of heart diseases, developing and implementing clinical decision tools for personalizing medical care, discovering the human health effects of intermittent fasting, and studying the influences of air pollution on major adverse health events.
-
Ngan F. Huang
Associate Professor of Cardiothoracic Surgery (Cardiothoracic Surgery Research) and, by courtesy, of Chemical Engineering
Current Research and Scholarly InterestsDr. Huang's laboratory aims to understand the chemical and mechanical interactions between extracellular matrix (ECM) proteins and pluripotent stem cells that regulate vascular and myogenic differentiation. The fundamental insights of cell-matrix interactions are applied towards stem cell-based therapies with respect to improving cell survival and regenerative capacity, as well as engineered vascularized tissues for therapeutic transplantation.
-
Gentaro Ikeda
Instructor, Medicine - Cardiovascular Medicine
BioDr. Ikeda is a physician-scientist who develops innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on his clinical experience as a cardiologist, he has become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin-angiotensin-aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, he moved to academia to conduct translational research. During his graduate training in the Egashira Lab, he focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. He obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. He realized the importance of translational research and the great potential of DDS to overcome many clinical problems. He developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. He published a first-author paper and received academic awards for his novel science. Since becoming a postdoctoral fellow in the Yang Lab, he has continued to build upon his previous training in translational research. He is currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for mitochondria-related diseases such as heart failure and mitochondrial disease.
-
Fumiaki Ikeno
Program Director (U.S) Japan Biodesign, Stanford Biodesign, Medicine - Med/Cardiovascular Medicine
BioProgram Director (U.S) Japan Biodesign, Stanford Biodesign
Researcher Cardiovascular Medicine, Stanford University
Faculty of Japan Reach, CARE (Center for Asian Health Research and Education) , Stanford University
Co-Director of Asia, SPARK Global, Stanford SPARK , Stanford University
Dr. Ikeno is a Researcher, Cardiovascular Medicine, Stanford University. In this role, he is responsible for pre clinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases. Currently, he is devoting himself to the international regulatory project between Japan and the United States, also known as "Harmonization by Doing", whose focus is to collaborate with regulatory agencies such as FDA, PMDA/MHLW, academia and industries for improving the regulatory process in the 2 largest medtech markets. Dr. Ikeno also devoted himself to found Japan biodesign program which is a collaborative program with University of Tokyo, Osaka University, Tohoku University, Japan Federation Medical Device Association, Ministry of Education Japan and Stanford biodesign program. Currently, Dr. Ikeno serves as the Program Director (US) for Japan Biodesign. Dr. Ikeno is co-founder and board member of US-Japan MedTech Frontier which is a non-profit cooperate to make a trans-pacific eco-system of medical device between Japan and USA.
After 9 years clinical practice as an interventional cardiologist and Family Doctor in rural areas of Japan, Dr. Ikeno came to Stanford as a Researcher and completed his Biodesign Certificate Program. Being part of the ecosystem in Silicon Valley, Dr. Ikeno participated in more than 200 medtech projects and 50 GLP studies as well as in the analysis of clinical trials for cardiovascular medicine (BARI2D, FAME, ReOPEN etc). His other academic consortium projects include Peripheral Academic Research Consortium, Global Consensus Working Group of Optical Coherence Tomography, and Japan-US consensus document for the treatment of critical limb ischemia.
Over the last decade, Dr. Ikeno has served as an advisor for medical device industries and currently serves as a chief medical officer of an incubation fund specific for medtech (Medventure Partners, Inc, Tokyo) as a spin-off from Innovation Network Corporation of Japan (INCJ) that is the largest government and private partnership fund in Japan. He is also serving as a chair of cardiovascular working group of APAN (Asian Pacific Advanced Network) that contributes the remote education, research activities, and tele-health using a specialized internet network. Dr.Ikeno is also serving as consulting faculty/lecturer roles in several universities in Japan including University of Tokyo, Osaka University, Tsukuba University etc. Dr. Ikeno has authored over 70 peer reviewed publications and textbooks and has been invited to lecture at international medical conferences. Dr. Ikeno is a council member of U.S.- Japan Council which is a non-profit organization by Japanese American. He is serving as a mentor for START-X MED which is an accelerating program for Stanford related entrepreneurs in medical fields.
Contact Information
Falk CVRC CV007
300 Pasteur Drive
Palo Alto, CA 94305-5406 -
John P.A. Ioannidis
Professor of Medicine (Stanford Prevention Research), of Epidemiology and Population Health and by courtesy, of Statistics and of Biomedical Data Science
Current Research and Scholarly InterestsMeta-research
Evidence-based medicine
Clinical and molecular epidemiology
Human genome epidemiology
Research design
Reporting of research
Empirical evaluation of bias in research
Randomized trials
Statistical methods and modeling
Meta-analysis and large-scale evidence
Prognosis, predictive, personalized, precision medicine and health
Sociology of science -
Haruka Itakura, MD, PhD
Assistant Professor of Medicine (Oncology)
BioDr. Haruka Itakura is an Assistant Professor of Medicine (Oncology) in the Stanford University School of Medicine, a data scientist, and a practicing breast medical oncologist at the Stanford Women’s Cancer Center. She is board-certified in Oncology, Clinical Informatics, Hematology, and Internal Medicine. Her research mission is to drive medical advances at the intersection of cancer and data science, applying state-of-the-art machine learning/artificial intelligence techniques to extract clinically actionable knowledge from heterogeneous multi-scale cancer data to improve patient outcomes. Her ongoing research to develop robust methodologies and apply cutting-edge techniques to analyze complex cancer big data was catapulted by an NIH K01 Career Development Award in Biomedical Big Data Science after obtaining a PhD in Biomedical Informatics at Stanford University. Her cancer research focuses on extracting radiomic (pixel-level quantitative imaging) features of tumors from medical imaging studies and applying machine learning frameworks, including radiogenomic approaches, for the integrative analysis of heterogeneous, multi-omic (e.g., radiomic, genomic, transcriptomic) data to accelerate discoveries in cancer diagnostics and therapeutics. Her current projects include prediction modeling of survival, treatment response, recurrence, and CNS metastasis in different cancer subtypes; detection of occult invasive breast cancer; and identification of novel therapeutic targets. Her ultimate goal is to be able to translate her research findings back to the clinical setting for the benefit of patients with difficult-to-treat cancers.
-
Sneha Shah Jain MD, MBA
Fellow in Graduate Medical Education
BioDr. Sneha S. Jain is a fellow in the Division of Cardiovascular Medicine. She previously was an internal medicine resident at Columbia/NewYork-Presbyterian, during which time she was selected as a Silverman Fellow in Healthcare Innovation. In this capacity, she worked with clinical and data science partners to build and deploy the technological infrastructure to identify patients with certain cardiac conditions earlier in the course of their disease. She received her MD from the Johns Hopkins School of Medicine and her MBA from Harvard Business School. She graduated with distinction from Duke University with a BS in Economics. During her time at Harvard Business School, she worked at Moderna Therapeutics and the VC firm Flare Capital.
Her research and entrepreneurial interests focus on the development and clinical trials of digital health and machine learning to reimagine healthcare delivery models and improve patient outcomes in cardiology. -
Siddhartha Jaiswal
Assistant Professor of Pathology
Current Research and Scholarly InterestsWe identified a common disorder of aging called clonal hematopoiesis of indeterminate potential (CHIP). CHIP occurs due to certain somatic mutations in blood stem cells and represents a precursor state for blood cancer, but is also associated with increased risk of cardiovascular disease and death. We hope to understand more about the biology and clinical implications of CHIP using human and model system studies.
-
Nerea Jimenez Tellez
Postdoctoral Scholar, Cardiovascular Institute
BioNerea is a Postdoctoral Scholar at Dr. Joseph Wu's lab. She earned her Bachelor's degree in Biochemistry at Universidad Complutense de Madrid (Spain). She was in an exchange program at the University of Saskatchewan (Canada) where she completed her Honours Thesis project on the Regulation of the Metastasis Suppressor Protein CREB3L1 in Dr. Deborah H Anderson's lab. She received her Masters' degree at Universidad de Alcalá (Spain) working at Dr. Isabel Liste Noya's lab on The role of p27Kip1 in the pluripotency and differentiation of dopaminergic neurons. She obtained her Ph.D. in Dr. Naweed Syed's lab studying the Cellular and molecular mechanisms underlying anesthetic-induced cytotoxicity, and their impact on learning and memory. She currently holds an ATRAC Postdoctoral Fellowship (Sept 2022- Aug 2023) titled "Toxicoepigenetic Effects of E-cigarette Exposure Using human iPSC-derived Organoids".